Nakamura Hideta, Miyagi Kazuya, Otsuki Mariko, Higure Yuuri, Nishiyama Naoya, Kinjo Takeshi, Nakamatsu Masashi, Haranaga Shusaku, Tateyama Masao, Fujita Jiro
Department of Infectious Disease, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Japan.
Intern Med. 2020 Nov 15;59(22):2945-2949. doi: 10.2169/internalmedicine.5244-20. Epub 2020 Sep 19.
Treatment with tocilizumab (TCZ) to block interleukin-6 (IL-6) signalling is predicted to mitigate cytokine release syndrome (CRS) caused by coronavirus disease 2019 (COVID-19). However, the adverse effects of TCZ on patients with COVID-19 remain unclear. We herein report a patient with COVID-19 treated with TCZ who developed acute hypertriglyceridaemia. Despite favipiravir treatment, acute respiratory distress syndrome developed in a 45-year-old patient with COVID-19; thus, TCZ was initiated. The triglyceride levels greatly increased after TCZ administration. Physicians should consider the negative impact of TCZ on the lipid profile in patients with COVID-19, although COVID-19-induced CRS itself may be an aggravating factor.
使用托珠单抗（TCZ）阻断白细胞介素-6（IL-6）信号传导有望减轻2019冠状病毒病（COVID-19）引起的细胞因子释放综合征（CRS）。然而，TCZ对COVID-19患者的不良影响仍不清楚。我们在此报告一名接受TCZ治疗的COVID-19患者出现了急性高甘油三酯血症。尽管使用了法匹拉韦治疗，但一名45岁的COVID-19患者仍发展为急性呼吸窘迫综合征；因此，开始使用TCZ治疗。给予TCZ后甘油三酯水平大幅升高。尽管COVID-19引起的CRS本身可能是一个加重因素，但医生应考虑TCZ对COVID-19患者血脂谱的负面影响。
